Pulmonary arterial hypertension (PAH) was considered as the leading cause of morbidity and mortality in systemic sclerosis (SSc) in the last two decades .The patients with SSc and PAH have about 50-60% estimated 3 year survival. There is proliferation and contraction of smooth muscle cells of the pulmonary arterioles in PAH.1